The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHZD.L Regulatory News (HZD)

  • There is currently no data for HZD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TSB Grant for next generation cancer diagnostics

16 Jun 2014 07:00

RNS Number : 6506J
Horizon Discovery Group plc
16 June 2014
 



PRESS RELEASE

16th June 2014

 

 

 

Horizon Discovery and LGC Awarded Technology Strategy Board Grant to Develop Standardization for Next Generation Cancer Diagnostics

 

Improving minimally invasive circulating DNA diagnostic assays supports implementation of stratified and personalized intervention strategies

 

Cambridge, UK, 16th June 2014: Horizon Discovery™ Group plc (LSE: HZD) (Horizon), the international life science company supplying research tools to organizations engaged in genomics research and the development of personalized medicines, today announces, together with LGC, an international life sciences measurement and testing company, that they have been offered a research grant of £360,224 ($608,000 USD) by the UK's innovation agency, the Technology Strategy Board, of which Horizon will receive more than half of the funding. The grant is awarded under the Technology Strategy Board's Collaborative Research and Development (CR&D) project 'Improving Cell and Tissue Analysis for Stratified Medicine' and will fund a joint project run by the Company's Horizon Diagnostics division in partnership LGC.

 

The project will fund the research and development of a portfolio of novel reference standard materials in order to serve a high need area of clinical diagnostics. The program will establish methods and cross platform data sets to standardize existing 'liquid biopsy' genetic diagnostic tests, to determine test sensitivity, and to help drive the development of new more sensitive systems as well as training and proficiency testing schemes for pathology laboratories.

 

Horizon will use its gene editing expertise and GENESIS™ platform (comprising rAAV, CRISPR/Cas9 and ZFN technologies) to precisely engineer cell lines carrying cancer genetic markers. These cell lines will be used to generate reference standard material including formalin-fixed paraffin embedded (FFPE) cell blocks and genomic DNA (gDNA). LGC, which is the UK's designated National Measurement Institute (NMI) for chemical and bioanalytical measurement, is developing methods using digital PCR for accurate value assignment of reference materials, and will test the reference standard material produced by Horizon. LGC is also developing these methods for highly accurate and sensitive detection of tumor DNA in the bloodstream.

 

Dr Paul Morrill, Senior Vice President of Reagent Products, at Horizon commented:

"We are delighted to receive this grant from the Technology Strategy Board that will enable Horizon, in partnership with LGC, to continue to drive developments in the cancer diagnostics field. Horizon is committed to investing in new, innovative areas related to cancer and diagnostics, supporting the increased implementation of stratified and personalized intervention strategies."

 

Carole Foy, Principal Scientist from LGC's Molecular and Cell Biology department, added: "The combination of Horizon's reference materials and LGC's assays - PCR primers and probes - gives the potential for development of kits that clinical laboratories can use with their existing platforms. These standardization tools will be invaluable in ensuring the accuracy of the results when detecting tumor DNA in the bloodstream."

 

 

ENDS

 

 

Notes to Editors

 

 

For further information from Horizon Discovery Group Plc, please contact:

 

Consilium Strategic Communications (Financial Media and Investor Relations)

Amber Bielecka / Mary-Jane Elliott / Jessica Hodgson / Matthew Neal

Tel: +44 (0) 20 3709 5701

Email: horizon@consilium-comms.com

 

Zyme Communications (Trade and Regional Media)

Katie Odgaard

Tel: +44 (0)7787 502 947

Email: katie.odgaard@zymecommunications.com

 

Panmure Gordon & Co. (NOMAD)

Corporate Finance: Freddy Crossley / Duncan Monteith / Fred Walsh

Broking: Tom Salvesen/ Adam Pollock

Tel: +44 20 7886 2500

 

Media enquiries for LGC:

Ellie Gadd

LGC Group

Email: ellie.gadd@lgcgroup.com

Tel: +44 (0)20 8943 8983

 

 

About Horizon Discovery www.horizondiscovery.com/

Horizon is a revenue-generating life science company supplying research tools to organizations engaged in genomics research and the development of personalized medicines. Horizon has a diverse and international customer base approaching 800 organizations, including major pharmaceutical, biotechnology and diagnostic companies as well as leading academic research centers. The Company supplies its products and services into multiple markets, estimated to total in excess of £29 billion by 2015.

 

Horizon's core capabilities are built around its proprietary translational genomics platform, GENESIS™, a high-precision and flexible suite of gene editing tools able to alter almost any endogenous gene sequence of human or mammalian cell-lines. Horizon has applied GENESIS™ to create over 550 X-MAN™ cell lines, accurately modeling the disease-causing mutations found in genetically based diseases. These 'patients-in-a-test-tube' are being used by customers to identify the effect of individual or compound genetic mutations on drug activity, patient responsiveness, and resistance, which may lead to the successful prediction of which patient sub-groups will respond to currently available and future drug treatments.

 

In addition, Horizon provides GENASSIST™ CRISPR and rAAV gene editing tools, custom cell line generation services for research and bioproduction applications, quantitative molecular reference standards, contract research and custom screening services, haploid cell lines (through Horizon's partner Haplogen), and custom shRNA development services and off-the-shelf validated shRNA (through Horizon's partner Sirion).

 

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange's AIM market under the ticker "HZD", for further information please visit: www.horizondiscovery.com

 

About LGC www.lgcgroup.com

LGC is an international life sciences measurement and testing company, which builds upon leading positions in sustainably growing markets. LGC provides reference materials, proficiency testing, genomics and analytical products and services which underpin the safety, health and security of the public to customers in the Pharmaceutical, Agricultural Bioscience, Food and Environment, Government and Academia, Security and Sports markets.

 

With headquarters in Teddington, South West London, LGC employs over 2,000 staff, operating out of 22 countries worldwide. Its operations are extensively accredited to international quality standards such as ISO/IEC 17025 and ISO Guide 34.

 

With a history dating back to 1842, LGC has been home to the UK Government Chemist for more than 100 years. It is the designated UK National Measurement Institute for Chemical and Bioanalytical measurement, providing metrology research, calibration and testing. LGC was privatised in 1996 and is now majority-owned by funds managed by Bridgepoint.

 

 

About the Technology Strategy Board

The Technology Strategy Board is the UK's innovation agency. Its goal is to accelerate economic growth by stimulating and supporting business-led innovation. Sponsored by the Department for Business, Innovation and Skills (BIS), the Technology Strategy Board brings together business, research and the public sector, supporting and accelerating the development of innovative products and services to meet market needs, tackle major societal challenges and help build the future economy. For more information please visit www.innovateuk.org.

 

As the UK's innovation agency, one of the main roles of the Technology Strategy Board is to achieve business and economic growth for the UK. One way the organisation supports this is through funding innovative Collaborative Research and Development (CR&D) projects. Collaborative research and development (R&D) encourages businesses and researchers to work together on innovative projects in strategically important areas of science, engineering and technology - from which successful new products, processes and services can emerge, contributing to business and economic growth. Find out more about the CR&D programme here: https://www.innovateuk.org/-/collaborative-r-d

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAFMGMVZKRGDZZ
Date   Source Headline
26th Jan 20187:00 amRNSBlock Listing Six Monthly Return
18th Dec 20177:00 amRNSAgreement with Roche Diagnostics
5th Dec 20177:00 amRNSHZD expand CRISPR license rights with ERS Genomics
24th Nov 20172:54 pmRNSTotal Voting Rights
3rd Oct 20172:10 pmRNSTotal Voting Rights
26th Sep 20177:00 amRNSInterim Results
25th Sep 20173:35 pmRNSHoldings in Company
8th Sep 20177:00 amRNSTrading Update
4th Sep 20173:42 pmRNSHolding(s) in Company
4th Sep 20172:37 pmRNSHolding(s) in Company
31st Aug 20173:30 pmRNSCompletion of Acquisition
24th Aug 20173:56 pmRNSHolding(s) in Company
24th Aug 20173:29 pmRNSHolding(s) in Company
23rd Aug 20178:18 amRNSCompletion of Placing
22nd Aug 20172:12 pmRNSUpdate on Acquisition of GE Healthcare Dharmacon
7th Aug 201710:19 amRNSResult of General Meeting
7th Aug 20177:00 amRNSDirector/PDMR Shareholding
24th Jul 20177:00 amRNSBlock Listing Application
19th Jul 20177:00 amRNSAcquisition and Proposed Placing to Raise £80m
7th Jul 20177:00 amRNSAdditional Listing
4th Jul 20171:55 pmRNSHoldings in Company
3rd Jul 20177:00 amRNSReference Standards support successful FDA filing
28th Jun 201710:57 amRNSResult of AGM
26th Jun 20171:54 pmRNSHolding(s) in Company
16th Jun 20177:00 amRNSAdditional Listing
6th Jun 20177:00 amRNSAdditional Listing
2nd Jun 20177:00 amRNSAnnual Report and Notice of Annual General Meeting
31st May 20177:00 amRNSAdditional Listing
30th May 20177:00 amRNSPreliminary Results Year Ended 31 December 2016
22nd May 20177:00 amRNSHZD Licenses New Gene Editing Technology Platform
9th May 20177:00 amRNSPerformance update in Immuno-Oncology
21st Apr 20177:00 amRNSAdditional Listing
19th Apr 20177:00 amRNSNotice of Results
11th Apr 20172:57 pmRNSHoldings in Company
7th Apr 20175:01 pmRNSGrant of Options
6th Apr 20177:00 amRNSAdditional Listing
30th Mar 20179:08 amRNSHoldings in Company
24th Mar 20177:00 amRNSAdditional Listing
23rd Mar 201711:24 amRNSHoldings in Company
20th Mar 201710:42 amRNSHoldings in Company
14th Mar 20177:00 amRNSAgreement for NIPT Reference Standards
23rd Feb 20177:00 amRNSSite Visit
20th Feb 20171:21 pmRNSHolding(s) in Company
15th Feb 20177:00 amRNSAdditional Listing
14th Feb 20177:00 amRNSMaster Service Agreement with Top 3 Pharma Company
10th Feb 20177:00 amRNSAdditional Listing
31st Jan 20173:06 pmRNSHolding(s) in Company
31st Jan 20177:00 amRNSIssue of Equity
26th Jan 20171:50 pmRNSHolding(s) in Company
24th Jan 20177:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.